ArticleInternational journal of clinical and experimental medicine2014
Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Polysaccharides from the Edible MushroomInternational journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inhibition of voltage-gated potassium channels (Kv) plays an important role in the cerebral hypoxia-induced cell death. The activity of Kv can be inhibited by 15-hydroxyeicosatetrienoic acid (15-HETE). Therefore, as the key enzyme which catalyzed the formation of 15-HETE, 15-LOX may be involved in Kv inhibition induced by cerebral hypoxia. In our study, Wistar rats cerebral arterial smooth muscle cells (CASMCs) were placed under the condition of hypoxia and control, 15-LOX was proved involved in hypoxia-induced vasoconstriction. Furthermore, 15-LOX gene over expression under normoxic condition, as well as 15-LOX gene knockout or inhibition under hypoxic condition was performed to investigate the expression and activity of Kv1.5 and Kv2.1 in CASMCs. Results showed that both hypoxia and 15-LOX over expression could cause Kv1.5 and Kv2.1 suppression, but no suppression was observed under hypoxic condition when 15-LOX gene was knockout or inhibited, which made 15-LOX a new target for the treatment of cerebral hypoxia. In conclusion, AA/15-LOX/15-HETE induces vasoconstriction by down-regulating Kv channels, and Kv2.1/1.5 channels are the targets. Our study also suggests a therapeutic strategy to improve ischemic vascular occlusion by lowering 15-HETE level and preventing Kv channel down-regulation, which makes 15-LOX as a new target for the treatment of cerebral hypoxia.
Indexed as
Identifiers
25550925PMC4276183W2206154709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.